Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

Trial Profile

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 22 Feb 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2025.
    • 22 Feb 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2025.
    • 11 Jan 2018 Planned number of patients changed from 2000 to 5000.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top